At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With NVAF With a History of Stroke or Transient Ischemic Attack - a Nationwide Retrospective Observational Study Using Claims Data in Japan
In Brief
An observational study evaluating Apixaban and Warfarin for Non-valvular Atrial Fibrillation. Completed, enrolled 193,565 participants across 1 site.
Detailed Summary
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention patients as Real World Evidence (RWE) on the effectiveness and safety of apixaban compared to warfarin in patients with non-valvular atrial fibrillation (NVAF).
Study Details
Timeline
Interventions
This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.